Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education

Front Page



UK Politics







Talking Point

In Depth

On Air

Low Graphics

Tuesday, June 1, 1999 Published at 16:15 GMT 17:15 UK


Obesity drug does keep you slim

Xenical can help people stay slim

Orlistat, a drug that has been hailed as Viagra for the obese, has been given the thumbs up by researchers who carried out the the first long-term study into its effect.

The drug was shown to help successful dieters keep weight off in a study published in the American Journal of Clinical Nutrition.

After losing eight per cent of their body weight over six months without the help of the drug, patients taking orlistat regained only around half the weight in the following six months compared to those carrying on without it.

In addition, the orlistat group showed a greater reduction in cholesterol than those not taking the drug.

However, AJCN Editor-in-Chief Charles Halstead said the results did not herald the arrival of a solution for obesity.

He wrote: "One must question why, after one year of treatment, three fourths of patients had begun the relentless process of weight regain."

Orlistat is marketed in the UK as Xenical. Manufacturers Roche Products believe it could be suitable for more than 15% of the UK population.

The drug works by blocking the absorption of fat in the gut and should be taken as part of a low-fat diet.

If people taking it eat a fatty diet, they experience a bloated and painful stomach and oily diarrhoea.

Patients given Xenical have been shown to lose an average of 10% in body weight over a year, compared with a 6% loss for those who only follow a low-fat diet.

Resource fears

[ image: More than 15 per cent of people could be suitable for the drug]
More than 15 per cent of people could be suitable for the drug
The Royal College of Physicians issued tough guidance on the prescription of obesity drugs earlier this year.

Under RCP guidelines overweight patients will only be prescribed drugs such as Xenical as a last resort if diet and exercise changes have failed..

The guidelines stipulate that treatment should be stopped if the patient does not lose 5% of their weight within three months.

The guidance followed concerns that huge demand for Xenical would drain NHS resources.

Conversely, some doctors were also concerned that health authorities tended to view obesity as a self-inflicted problem and were reluctant to pay for its treatment.

The Obesity Resource Information Centre (ORIC) has warned that some patients lose more weight than others on Xenical.

The ORIC stressed that Xenical is not a miracle cure and should only be used as part of a weight management programme.

Obese people are defined as those whose weight in kilos divided by their height in metres squared is over 30. This measurement is known as the Body Mass Index.

Xenical is likely to be available to people with a BMI of over 28, provided they have other associated risk factors such as diabetes.

Advanced options | Search tips

Back to top | BBC News Home | BBC Homepage | ©

Health Contents

Background Briefings
Medical notes

Relevant Stories

27 May 99 | Health
Task force takes on obesity

19 Apr 99 | Health
Obesity rise 'founded on denial'

13 Jan 99 | Health
Tough guidance on obesity drugs

13 Jan 99 | Health
Fat hope for an obesity cure

21 Sep 98 | Health
Fears of stampede over fat-busting drug

31 Jul 98 | Health
Pill gets go-ahead for battle of the bulge

Internet Links

American Journal of Clinical Nutrition



Obesity and weight control

The BBC is not responsible for the content of external internet sites.

In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99